(Q38093671)

28 August 2017

title

Oxycodone combined with opioid receptor antagonists: efficacy and safety (English)

1 reference

28 August 2017

0 references

0 references

0 references

0 references

Mellar Davis

1

1 reference

28 August 2017

Harold W Goforth

series ordinal

2

1 reference

28 August 2017

Pam Gamier

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

28 March 2013

1 reference

Expert Opinion on Drug Safety

28 August 2017

published in

1 reference

28 August 2017

volume

12

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

389-402

1 reference

Are there cost benefits to fentanyl for breakthrough pain?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Patient centered decision making in palliative cancer treatment: a world of paradoxes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Null hypothesis significance testing: a review of an old and continuing controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Choice of effect measure for epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Comparison of epidural morphine and oxycodone for pain after abdominal surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Retracted: High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor-Gs Coupling Underlying Opioid Tolerance and Dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Paradoxical and subtype-specific effects of opiate antagonists on the expression of opioid receptors in rat brain cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ultra-low dose naloxone upregulates interleukin-10 expression and suppresses neuroinflammation in morphine-tolerant rat spinal cords

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Opioid receptor heteromers in analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Evidence from basic research for opioid combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Inverse agonism gains weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Opioid formulations designed to resist/deter abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

A profile of OxyContin addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Motives, diversion and routes of administration associated with nonmedical use of prescription opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Development and preliminary experience with an ease of extractability rating system for prescription opioids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Approaches to improve pain relief while minimizing opioid abuse liability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Opioids and the gut: pharmacology and current clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Low-dose oral naloxone reverses opioid-induced constipation and analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Oral naloxone in opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Assessing the quality of randomized controlled trials. Current issues and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

High doses of oxycodone-naloxone combination may provide poor analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

The missing voice of patients in drug-safety reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Assessing equivalence and noninferiority

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Opioid-induced bowel dysfunction: pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.783564

10.1517/14740338.2013.783564

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference